<DOC>
	<DOCNO>NCT02293265</DOCNO>
	<brief_summary>This non-drug interventional cross-sectional study , screen visit study visit occur day . Investigational product administer . Approximately 790 subject severe asthma screen achieve total least 750 evaluable study subject . The study include run-in follow-up period . This study provide reliable description severe asthma patient landscape respect potential eligibility treatment mepolizumab , omalizumab , reslizumab . This study aim estimate potential overlap patient eligible treatment mepolizumab eligible treatment omalizumab and/or reslizumab . Additionally , current study also ascertain describe reslizumab eligibility respect mepolizumab omalizumab , severe asthma patient population .</brief_summary>
	<brief_title>Cross-sectional Study Identification Description Severe Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>At least 12 year age study visit . Participants eligible enrolment entry study must meet following definition severe asthma , base definition severe asthma describe European Respiratory Society/ American Thoracic Society ( ERS/ATS ) Guidelines severe asthma : Asthma require treatment guideline suggest medication Global Initiative Asthma ( GINA ) step 45 asthma previous year ( i.e. , least 12 month ) . Patients must treat high dose ICS PLUS least one following : LABA , leukotriene modifier , theophylline , continuous near continuous systemic corticosteroid ( i.e. , maintenance systemic corticosteroid â‰¥50 % previous year ) . SPECIAL CIRCUMSTANCE : If patient fix dose combination medication , maximum recommend dose ICS/LABA combination per local label acceptable . Able give write informed consent prior participation study , include ability comply requirement restriction list consent form . Participants must able read , comprehend , write level sufficient complete study related material . A parent legal guardian must provide informed consent participant less 18 year age study visit ( less minimum age consider adult per local law ) . Participants participate interventional clinical trial asthma within past 12 month prior Visit 1 ( NOTE : subject participate observational study investigational product procedure administer subject exclusion criterion )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>mepolizumab</keyword>
	<keyword>omalizumab</keyword>
	<keyword>SB-240563</keyword>
	<keyword>Severe Asthma</keyword>
	<keyword>reslizumab</keyword>
</DOC>